Copy to clipboard 
SeaSpine announced 2Q17 revenue of US $34.2MM, +3.0% vs. 2Q16, and 1H17 revenue of $66.1MM, +2.3% vs. 1H16.
| 2Q17 | 2Q16 | $ Change | % Change | |
| Spine | $16.6 | $16.4 | $0.2 | 1.2% |
| Orthobiologics | $17.6 | $16.8 | $0.8 | 4.7% |
| Total | $34.2 | $33.2 | $1.0 | 3.0% |
| 1H17 | 1H16 | $ Change | % Change | |
| Spine | $31.4 | $31.1 | $0.2 | 0.7% |
| Orthobiologics | $34.7 | $33.5 | $1.3 | 3.8% |
| Total | $66.1 | $64.6 | $1.5 | 2.3% |
2Q17 Geographic results: U.S. $30.4MM, +1.1%; ex-U.S. $3.8MM, +20.5%
Performance highlights:
- U.S. orthobiologics revenue of $16.0MM supported by recently-added distributors, while ex-U.S. sales fell by $0.3MM primarily due to decreased Latin America sales
- Spinal hardware supported by stocking orders from recently-added Latin America distributor; U.S. hardware sales fell by $0.7MM to end at $14.4MM, primarily due to lower price and decreased demand for legacy systems
- In 1H17, ~30% of U.S. spinal instrumentation revenue generated by key new distributors
- Launched Daytona Small Stature Pediatric Deformity system
- Completed alpha launch of reusable rapid graft delivery system; full launch slated for early 2018
- After quarter’s close, announced full commercial launch of Mariner® modular pedicle-based system for posterior spinal fixation and limited launch of the SkipJack™ expandable interbody
- On track for up to 10 new or next-gen products and line extensions in 2017
- Expecting Shoreline anterior cervical fixation to move into full launch by end of 3Q
- Due to growth from new products and a stronger distributor base, increased low end of 2017 revenue guidance; was $129MM, now range is $130MM-$133MM
Source: SeaSpine Holdings Corporation
SeaSpine announced 2Q17 revenue of US $34.2MM, +3.0% vs. 2Q16, and 1H17 revenue of $66.1MM, +2.3% vs. 1H16.
Q17
Q16
$ Change
% Change
Spine
$16.6
$16.4
$0.2
1.2%
...
SeaSpine announced 2Q17 revenue of US $34.2MM, +3.0% vs. 2Q16, and 1H17 revenue of $66.1MM, +2.3% vs. 1H16.
| 2Q17 | 2Q16 | $ Change | % Change | |
| Spine | $16.6 | $16.4 | $0.2 | 1.2% |
| Orthobiologics | $17.6 | $16.8 | $0.8 | 4.7% |
| Total | $34.2 | $33.2 | $1.0 | 3.0% |
| 1H17 | 1H16 | $ Change | % Change | |
| Spine | $31.4 | $31.1 | $0.2 | 0.7% |
| Orthobiologics | $34.7 | $33.5 | $1.3 | 3.8% |
| Total | $66.1 | $64.6 | $1.5 | 2.3% |
2Q17 Geographic results: U.S. $30.4MM, +1.1%; ex-U.S. $3.8MM, +20.5%
Performance highlights:
- U.S. orthobiologics revenue of $16.0MM supported by recently-added distributors, while ex-U.S. sales fell by $0.3MM primarily due to decreased Latin America sales
- Spinal hardware supported by stocking orders from recently-added Latin America distributor; U.S. hardware sales fell by $0.7MM to end at $14.4MM, primarily due to lower price and decreased demand for legacy systems
- In 1H17, ~30% of U.S. spinal instrumentation revenue generated by key new distributors
- Launched Daytona Small Stature Pediatric Deformity system
- Completed alpha launch of reusable rapid graft delivery system; full launch slated for early 2018
- After quarter’s close, announced full commercial launch of Mariner® modular pedicle-based system for posterior spinal fixation and limited launch of the SkipJack™ expandable interbody
- On track for up to 10 new or next-gen products and line extensions in 2017
- Expecting Shoreline anterior cervical fixation to move into full launch by end of 3Q
- Due to growth from new products and a stronger distributor base, increased low end of 2017 revenue guidance; was $129MM, now range is $130MM-$133MM
Source: SeaSpine Holdings Corporation
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.
